Patent ID: 8906625

Claim:
A method of predicting the likelihood of distant recurrence-free survival for a human subject diagnosed with breast cancer, comprising: assaying a level of an RNA transcript of N-acetyltransferase 1 (NAT1) in a tumor sample obtained from said subject using a primer comprising a nucleotide sequence selected from SEQ ID NO:226 and SEQ ID NO:227; normalizing the RNA level of NAT1 against the level of one or more reference genes to obtain a normalized expression level of NAT1; using the normalized expression level of NAT1 to generate information comprising a prediction of the likelihood of distant recurrence-free survival for said subject, wherein the normalized expression level of NAT1 is positively correlated with a longer distant recurrence-free survival, and wherein distant recurrence-free survival is the time from surgery until the first diagnosis of distant recurrence.